Shukra Pharmaceuticals ‘s Latest Q1 Report: Profit Up by 16.67% Year-on-Year

The comprehensive analytics outlining the performance and outlook of Shukra Pharmaceuticals Limited‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Shukra Pharmaceuticals Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -84.24 %. However, it did see a marginal slip of -70.8 % from the previous quarter. Expenses decreased slightly by -63.26 % quarter-on-quarter, aligning with the annual decline of -88.04 %. Operating profit, while up 138.24 % compared to last year, faced a quarter-on-quarter dip of -81.72 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 23.8 %, but a shrinkage of -15.21 % sequentially. Other income fell by -47.86 % compared to the last quarter, despite an annual growth of 13.25 %. Interest expenses dropped significantly by -14.29 % from the previous quarter, yet the year-over-year decrease remains at a moderate -33.33 %. Depreciation costs climbed by 28.85 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 45.65 %. Profit before tax grew annually by 90.48 % but saw a reduction from the preceding quarter by -84.67 %.
Tax expenses as a percentage of profits increased slightly by 37.61 % compared to last year, with a more notable quarter-on-quarter increase of 15.32 %. Net profit rose by 16.67 % year-on-year but witnessed a -87.72 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -81.36 % but a quarterly fall of -96.98 %. In summary, Shukra Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Shukra Pharmaceuticals Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -84.24 % year-on-year, although there was a slight dip of -70.8 % from the previous quarter. Expenses decreased by -88.04 % compared to the previous year, with a decrease of -63.26 % quarter-on-quarter. Operating Profit surged by 138.24 % annually, and saw a -81.72 % decrease from the last quarter.
Net Profit showed yearly increase of 16.67 %, and experienced a -87.72 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -81.36 % annually, however dipped by -96.98 % compared to the last quarter. In essence, while Shukra Pharmaceuticals Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.